COVID-19 Vaccine Linked to Longer Survival in Advanced Cancer Patients
Patients with advanced lung or skin cancer who received a COVID-19 mRNA vaccine within 100 days of beginning immunotherapy experienced significantly longer survival rates than those who did not, according to research presented today.
The analysis, examining medical records from over 1,000 patients at the University of Texas MD Anderson Cancer Center, suggests a potential breakthrough in harnessing the power of mRNA technology to enhance cancer treatment. Researchers from the University of Florida and MD Anderson found that among 180 advanced lung cancer patients, median survival nearly doubled – from 20.6 months to 37.3 months – in those vaccinated before or after starting immunotherapy. Similar improvements were observed in metastatic melanoma patients. This discovery offers a potential new avenue for improving outcomes in cancers that often have limited treatment options.
“The implications are extraordinary – this could revolutionize the entire field of oncologic care,” said Dr. Elias Sayour, a pediatric oncologist at UF Health. “We could design an even better nonspecific vaccine to mobilize and reset the immune response, in a way that could essentially be a universal, off-the-shelf cancer vaccine for all cancer patients.” The study builds on prior research demonstrating that stimulating the immune system with an mRNA vaccine, similar to those used for COVID-19, can trigger a strong antitumor response. Further research into immunotherapy is ongoing.
Researchers emphasize that these findings are preliminary and require confirmation through randomized clinical trials. However, the results have spurred plans for a large clinical trial through the UF-led OneFlorida+ Clinical Research Network. “Although not yet proven to be causal, this is the type of treatment benefit that we strive for and hope to see with therapeutic interventions — but rarely do,” said Dr. Duane Mitchell, director of the UF Clinical and Translational Science Institute. The next step involves launching a large clinical trial to validate these promising results.
